This story was originally published Dec. 31, 2012.

The next-gen sequencing sector kicked off 2012 with a hostile attempt from Roche to take over Illumina and ended with both BGI and Illumina pursuing Complete Genomics, bookending a year that saw a number of business deals — both successful and failed — from companies looking to bolster their positions in the increasingly competitive next-gen world.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.